Thomas Bartlett

1 month ago | myastheniagravisnews.com | Allen Francis |Katherine Poinsatte |Thomas Bartlett |Margarida Maia

Do you ever use a phrase often without fully appreciating its meaning, especially its meaning to others? I’ve been thinking about the phrase “seeing double” for some time. My twin brother, Aaron, was diagnosed with myasthenia gravis (MG) in 1999, and he lives with a lot of its symptoms, such as muscle weakness. Since stress and anger can cause MG flare-ups, he’s spent decades learning how to mitigate both. He hasn’t been able to work since his diagnosis.

1 month ago | myastheniagravisnews.com | Thomas Bartlett |Andrea Lobo |Margarida Maia |Shawna Barnes

As the result of his professional background working at companies such as Apple and Dell and a life sciences consulting firm, Thomas Bartlett found himself needing to make a difference in the world of myasthenia gravis (MG). He began by consulting for pharmaceutical companies in the MG space, and now he speaks about applied technologies to improve quality of life through real-time data acquisition and analysis.

1 month ago | myastheniagravisnews.com | Margarida Maia |Marisa Wexler |Thomas Bartlett |Shawna Barnes

Tacrolimus, an immunosuppressant sometimes used off-label to treat adults with myasthenia gravis (MG), eased symptoms of the disease in about four in every five children with juvenile MG, with few side effects. That’s according to a meta-analysis of nine studies from China and Japan, which also found tacrolimus reduced the need for corticosteroids, often used when other treatments fail to keep MG symptoms under control.

Apr 25, 2024 | biorxiv.org | Thomas Bartlett

AbstractWe show much-improved accuracy of inference of GRN (gene regulatory network) structure resulting from the use of an epigenomic prior network. We also find that DNAme data are very effective for inferring the epigenomic prior network, recapitulating known epigenomic network structure found previously from chromatin accessibility data, and in some cases providing potential TF cis-regulations for eight times as many genes compared to chromatin accessibility data.